Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 20/20 | 1.00 |
| ▸ | PLK3 | Q9H4B4 | 9/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.80 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13573236 | 1.00 | PLK1 (1.00) | PLK1PLK3CYP3A4CYP2C9 | |
| SCHEMBL5003640 | 0.93 | PLK1 (0.88) | PLK1PLK3CYP3A4CYP2C9 | |
| SCHEMBL4406023 | 0.92 | PLK1 (0.85) | PLK1PLK3CYP3A4CYP2C9 | |
| SCHEMBL4404515 | 0.92 | PLK1 (1.00) | PLK1PLK3CYP3A4CYP2C9 | |
| SCHEMBL4551011 | 0.90 | PLK1 (0.85) | PLK1PLK3CYP3A4CYP2C9 | |
| SCHEMBL3566304 | 0.90 | PLK1 (0.85) | PLK1PLK3CYP3A4CYP2C9 | |
| SCHEMBL4551471 | 0.90 | PLK1 (1.00) | PLK1PLK3CYP3A4CYP2C9 | |
| SCHEMBL4551474 | 0.90 | PLK1 (1.00) | PLK1PLK3CYP3A4CYP2C9 | |
| SCHEMBL4551487 | 0.89 | PLK1 (0.82) | PLK1PLK3CYP3A4CYP2C9 | |
| SCHEMBL3150935 | 0.89 | PLK1 (1.00) | PLK1PLK3CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1924572-B1 | REGIOSELECTIVE PROCESS FOR PREPARING BENZIMIDAZOLE THIOPHENES | SMITHKLINE BEECHAM CORP (US) | 2009-12-30 | — | — | EP | disclosed |
| WO-2009151914-A1 | METHODS FOR TREATING NEOPLASMS WITH A COMBINATION OF A PLK INHIBITOR AND RETINOID | SMITHKLINE BEECHAM CORPORATION (US) | 2009-12-17 | — | — | WO | disclosed |
| US-20080249301-A1 | Regioselective Process for Preparing Benzimidazole Thiophenes | SMITHKLINE BEECHAM CORPORATION | 2008-10-09 | — | — | US | disclosed |
| US-20080249301-A1 | Regioselective Process for Preparing Benzimidazole Thiophenes | SMITHKLINE BEECHAM CORPORATION | 2008-10-09 | — | — | US | disclosed |
| US-20080249301-A1 | Regioselective Process for Preparing Benzimidazole Thiophenes | SMITHKLINE BEECHAM CORPORATION | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249301-A1 | Regioselective Process for Preparing Benzimidazole Thiophenes | CYP3A4, CYP2C19, CYP2B6 | PLK1 1718/4885PLK3 2097/4885CYP3A4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.